uniQure Projects $0.93 Loss and Faces Securities Lawsuits
uniQure forecasts a $0.93 per share loss and $4.7 million quarterly revenue, reflecting a negative P/E of -4.26 and a 66.94 price-to-sales ratio. The company faces multiple class action lawsuits over alleged securities violations tied to its Pivotal Study design and BLA approval delays.
1. Earnings Forecast and Financial Metrics
uniQure is set to report a $0.93 per share quarterly loss on approximately $4.7 million in revenue, yielding a negative price-to-earnings ratio of -4.26. Its price-to-sales ratio of 66.94 and enterprise value-to-sales multiple of 33.23 highlight high valuation despite ongoing losses.
2. Class Action Lawsuits
The company is targeted by three separate class action lawsuits alleging false and misleading statements regarding its Pivotal Study design and comparisons to the ENROLL-HD data set. Claims cover share purchases between late September and October 2025, with an April 13, 2026 filing deadline for affected investors.
3. Regulatory Approval Delays
Allegations centered on study design discrepancies have reportedly delayed full FDA approval of uniQure's Biologics License Application, pushing back commercialization timelines for its gene therapy candidates. These regulatory setbacks could extend R&D spending and defer revenue recognition.
4. Liquidity and Debt Position
Despite these challenges, uniQure maintains a debt-to-equity ratio of 0.29 and a current ratio of 7.12, indicating strong short-term liquidity. However, a negative enterprise value-to-operating cash flow ratio of -3.42 and an earnings yield of -23.48% underscore continued cash burn concerns.